All three tenses have at least two readings, so the archetype blend applies as printed.
Of the nine metrics, 8 read as filed from the record and 1 is an SI estimate, each with its reasoning, its confidence and what would change it on its card.
What did they actually do?
Has it survived what it has been through?
1 warning event since 2017; the latest 2017-05-17.
From the record
Fennec Pharmaceuticals Inc.'s filings since 2017 show 1 warning event: an auditor change (8-K item 4.01, the latest 2017-05-17) (its current reports).
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
What has it actually done, year after year?
10 filed years; profitable in 0 of 9.
From the record
Fennec Pharmaceuticals Inc.'s 10 filed years say what it did: it rose in 3 of 4 years; the deepest fall was 6% from fiscal 2024 to fiscal 2025; net income was positive in 0 of 9 of those years (its annual reports).
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
How has it treated the people who own it?
SI estimate 8.3/10, confidence 35 of 100 (one part).
SI estimate Inferred, not read as filed
From the record
SI estimate, not a filed reading: Fennec Pharmaceuticals Inc.'s shareholder treatment is put at 8.3 of 10 with a confidence of 35 of 100, because read from one part only, the share count over the years, which ranks in the top 17% of 146 in its family; fewer than two of the parts can be read: the share count over the years, and the cash returned against a positive operating cash flow or net income. A filing that carries the missing parts replaces this estimate with the filed reading.
What are they doing right now?
Is it financially healthy right now?
ROE -27%: lost 27¢ per shareholder dollar. Leverage 50%: owes 50¢ per asset dollar.
From the record
Return on equity: in the fiscal year ended 2025-12-31, Fennec Pharmaceuticals Inc. lost about 27 cents for every dollar of shareholders' money. Leverage: it owed about 50 cents per dollar of assets, and net share issuance: its share count grew 4.7% over the year (the filed statements).
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
How strong is its position in its industry?
top 26% of 102 in its family; net margin -21.8%.
From the record
Fennec Pharmaceuticals Inc.'s standing among 102 graded names in its industry family: revenue of $45 million in fiscal 2025 ranks in the top 42% by size; a net margin of -21.8% ranks in the top 29%; revenue growth of 207.4% a year over the last 3 filed years ranks in the top 6% (its annual reports).
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
What are the people in charge doing?
top 46% of 110 in its family for leadership; chief executive since 2024.
From the record
Fennec Pharmaceuticals Inc.'s leadership, from its insiders' filings and its current reports: the chief executive on the record is Hackman, Jeffrey S. (Chief Executive Officer, as filed), filing under that title since 2024-08-19, 2.2 years (bottom 27% of its family); the 10 officers and directors filing in the last fifteen months have been on the record a median of 8.1 years (top 11%); 5 officer or director changes were reported on Form 8-K since 2023-11-13, against the 10 people in charge now (bottom 47%; fewer changes for each person reads higher) (the Form 4 record, its Form 8-K reports). Years count from a person's first filing in the SEC's data sets, which begin in 2006, so each is a floor.
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
What are they set up to do next?
How much room does it have to grow?
bottom 47% of 92 in its family for room to expand.
From the record
Fennec Pharmaceuticals Inc.'s room to grow, from the newest filed statements (fiscal 2025): cash of $37 million against no long-term debt tagged leaves 52.1% of its assets as net cash, top 29% of its family; cash from operations less capital spending is -27.9% of revenue (top 29%); research spending of 0.6% of revenue (bottom 1%) (its annual report).
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
What could actually drive growth from here?
bottom 16% of 100 in its family for growth drivers.
From the record
Fennec Pharmaceuticals Inc.'s growth drivers, from the filed years to fiscal 2025: the newest year grew -6.1% (bottom 32%); research spending grew -58.6% a year (bottom 1%) (its annual reports). Fennec Pharmaceuticals Inc. tags no split of its revenue by line in the annual report on file, so growth by line cannot be read here; research and capital spending are on the trend.
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
Did its newest year beat what its own record pointed to?
bottom 46% of 72 in its family for expectations against reality.
From the record
Fennec Pharmaceuticals Inc.'s newest year against its own record: revenue of $45 million in fiscal 2025 came in 83.1% below the $264 million its prior three years' pace pointed to (bottom 2% of its family); net income of $10 million against a prior three-year average of $13 million (top 39%); a net margin of -21.8% against losses larger than its revenue before (top 24%) (its annual reports).
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
The grade is the company against its own industry, from its filings. It is not a view on the share price. How the grade is made